Open Access

DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway

  • Authors:
    • Zheng Yang
    • Hanrui Chen
    • Man Shu
    • Yunjian Zhang
    • Ling Xue
    • Yuan Lin
  • View Affiliations

  • Published online on: December 28, 2018     https://doi.org/10.3892/ol.2018.9874
  • Pages: 2107-2116
  • Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Deleted in liver cancer 2 (DLC2) is a tumor suppressor, associated with various types of cancer. The aim of the present study was to analyze the expression of DLC2 in breast cancer, its clinical significance and its effect on breast cancer cell behavior. The expression of DLC2 was evaluated by immunohistochemistry in 131 cases of breast cancer. Associations among DLC2 expression and clinicopathological features were analyzed, and its effects on proliferation, motility, migration and invasion in DLC2‑knockdown breast cancer cell lines were observed. The results indicated that DLC2 was expressed in 42.75% of breast cancer cases (56/131) and in 79.39% of adjacent normal tissues (104/131). Lower expression of DLC2 in breast cancer was associated with tumor differentiation (P<0.001), lymph node metastasis (P<0.001) and poor prognosis (P<0.001). The silencing of the DLC2 gene in human breast cancer cell indicated an increased number of cells entering S phase, and increased abilities of clone formation, cell migration and invasion. Downregulated expression of DLC2 was associated with activated Ras homolog family member A and decreased Rac family small GTPase 1, cell division cycle 42 and Rho‑associated protein kinase‑2 expression levels, indicating that DLC2 may serve a regulatory function in breast cancer cell proliferation and invasion via the RhoGTPase pathway. The results of the present study suggested that DLC2 serves as a suppressor gene in the development of breast cancer and may be a prognostic marker for patients with breast cancer.
View Figures
View References

Related Articles

Journal Cover

February-2019
Volume 17 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang Z, Chen H, Shu M, Zhang Y, Xue L and Lin Y: DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway. Oncol Lett 17: 2107-2116, 2019
APA
Yang, Z., Chen, H., Shu, M., Zhang, Y., Xue, L., & Lin, Y. (2019). DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway. Oncology Letters, 17, 2107-2116. https://doi.org/10.3892/ol.2018.9874
MLA
Yang, Z., Chen, H., Shu, M., Zhang, Y., Xue, L., Lin, Y."DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway". Oncology Letters 17.2 (2019): 2107-2116.
Chicago
Yang, Z., Chen, H., Shu, M., Zhang, Y., Xue, L., Lin, Y."DLC2 operates as a tumor suppressor gene in breast cancer via the RhoGTPase pathway". Oncology Letters 17, no. 2 (2019): 2107-2116. https://doi.org/10.3892/ol.2018.9874